Phase I Trial of Intravenous Lymphokine MAF
Preparation of large enough quantities of purified, chemically characterized biological response modifiers (BRMs) has required years of preparative and analytic studies leading to isolation and characterization of biologically active, pure peptides. Prior to the presently limited use of such peptides, phase I studies were carried out to determine biological effects of more complex preparations in patients, as in the case of human leukocyte interferon (Strander et al., 1973) and thymosin fraction 5 (Costanzi et al., 1977). Complex lymphokine fractions have been used for inducing local skin inflammatory reactions (Papermaster et al., 1976) and to treat dermal tumor lesions by direct intralesional injection (Paradinas et al., 1982) and also have been administered intravenously by Dumonde et al. (1981) to patients with disseminated cancer at low to moderate doses [1–2 ml delivering a total of 70 mg protein (Organon preparation)] and roughly equivalent to our unitage of between 200 and 500 units (Paradinas et al., 1982).
KeywordsMigration Inhibitory Factor Serum Iron Serum Protein Electrophoresis Underlying Heart Disease Inferior Myocardial Infarction
Unable to display preview. Download preview PDF.
- Dumonde, D. C., Paradinas, F., Pulley, M., Southcott, B., O’Connell, D., Robinson M., and den Hollander, F., 1981, A histological study of intradermal and intralesional injection of human lymphoid cell line lymphokine (LCL-LK) in patients with advanced cancer, J. Clin. Hematol. Oncol. 11:130.Google Scholar
- Dunn, P. A., Eaton, W. R., Lopatin, E., Tyrer, H., McEntire, J. E., Papermaster, B. W., Miller, A., and Vosika, G., 1982, Macrophage activation by lymphokine factors (MAF) as measured by phagocytosis, metabolic products, and tumor cell cytotoxicity: Correlation of multiparameter functional assays, in: Human Lymphokines: The Biological Immune Response Modifiers (A. Khan and N. O. Hill, eds.), pp. 67–82, Academic Press, New York.CrossRefGoogle Scholar
- Goldstein, A. L., Low, T. L. K., Thurman, G. B., Zatz, M. M., McClure, J. E., Hall, N., and Hu, S. K., 1981, Recent developments in the chemistry, biology and clinical applications of thymosin, in: Cellular Responses to Molecular Modulators (L. W. Mozes, J. Schultz, W. A. Scott, and R. Werner, eds.), pp 237–247, Academic Press, New York.Google Scholar
- McEntire, J. E., Dunn, P. A., Gehrke, C. W., and Papermaster, B. W., 1981, Isolation and purification of an acid-soluble polypeptide with lymphokine properties from a human lymphoblastoid cell line, in: Lymphokines and Thymic Hormones: Their Potential Utilization in Cancer Therapeutics (A. L. Goldstein and M. A. Chirigos, eds.) pp. 109–119, Raven Press, New York.Google Scholar
- Papermaster, B. W., Holterman, O. A., Klein, E., Parmett, S., Dobkin, D., Laudico, R., and Djerassi, I., 1976, Preliminary observations on tumor regressions induced by local administration of a lymphoid cell culture supernatant fraction in patients with cutaneous metastatic lesions, Clin. Immunol. Immunopathol. 5:48–59.PubMedCrossRefGoogle Scholar
- Paradinas, F. J., Southcott, B. ML, O’Connell, D., den Hollander, F., Schuurs, A. H., Pulley, M. S., and Dumonde, D. C., 1982, Changes induced by local injection of human lymphoid cell lymphokine into dermal metastases of breast carcinoma: A light and electron microscopial study, J. Pathol. 138:309–323.PubMedCrossRefGoogle Scholar
- Pestka, S., Maeda, S., Hobbs, D. S., Levy, W. P., McCandliss, R., Stein, S., Moschera, J., and Staehelin T., 1981, The human interferon, in: Cellular Responses to Molecular Modulators (L. W. Mozes, J. Schultz, W. A. Scott, and R. Werner, eds.), pp. 455–489, Academic Press, New York.Google Scholar
- Sama, G., Figlin, R., and McCarthy, S., 1983, Phase I study of Wellferon (human lymphoblastoid α-interferon) as cancer therapy: Clinical results, J. Biol. Resp. Modif. 2:187–195.Google Scholar